Muscarinic receptors as targets for anti-inflammatory therapy

Current Opinion in Investigational Drugs

Volumn 11, Issue 11, 2010, Pages 1239-1245

  Sales, María Elena ^a  

^a Centre de Estudios Farmacologicos y Botanicos   (Argentina)

Author keywords

Ach; atopic dermatitis; COPD; inflammation; intestinal inflammation; muscarinic antagonist; muscarinic receptor; sepsis

Indexed keywords

ACETYLCHOLINE; ACLIDINIUM BROMIDE; ATROPINE; BUDESONIDE; BUNGAROTOXIN RECEPTOR; CHOLINE ACETYLTRANSFERASE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE; FORMOTEROL; IPRATROPIUM BROMIDE; MECAMYLAMINE; METHOCTRAMINE; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINIC ACID; OXITROPIUM BROMIDE; PROCYCLIDINE; STRAMONIUM; TIOTROPIUM BROMIDE;

ADJUVANT THERAPY; AIRWAY REMODELING; ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATOPIC DERMATITIS; CATABOLISM; CHOLINERGIC SYSTEM; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG TARGETING; ENDOTOXEMIA; ENTERITIS; ENZYME SYNTHESIS; EUKARYOTIC CELL; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; IRRITABLE COLON; NERVE CELL; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PROKARYOTIC CELL; REVIEW; SEPSIS; SKIN INFLAMMATION; SUPPURATIVE HIDRADENITIS;

EID: 78650313173     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Miller SL, Urey HS: Organic compound synthesis on the primitive earth. Science (1959) 130(3370):245-251.
2. Abreu-Villaa Y, Filgueiras CC, Manhães AC: Developmental aspects of the cholinergic system. Behav Brain Res (2010):doi:10.1016/j. bbr.2009.12.049.
3. Wessler I, Kirkpatrick CJ, Racké K: Non-neuronal acetylcholine, a locally acting molecule, widely distributed in biological systems: Expression and function in humans. Pharmacol Ther (1998) 77(1):59-79.
4. Grando SA: Biological functions of keratinocyte cholinergic receptors. J Investig Dermatol Symp Proc (1997) 2(1):41-48.
5. Wessler I, Kirkpatrick CJ, Racké K: The cholinergic pitfall: Acetylcholine, a universal cell molecule in biological systems, including humans. Clin Exp Pharmacol Physiol (1999) 26(3): 198-205.
6. Caulfield MP, Birdsall NJ: International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev (1998) 50(2):279-290.
7. Wessler I, Kirkpatrick CJ: Acetylcholine beyond neurons: The non-neuronal cholinergic system in humans. Br J Pharmacol (2008) 154(8):1558-1571.
8. Racké K, Matthiesen S: The airway cholinergic system: Physiology and pharmacology. Pulm Pharmacol Ther (2004) 17(4):181-198.
9. McCudden CR, Hains MD, Kimple RJ, Siderovski DP, Willard FS: G-protein signaling: Back to the future. Cell Mol Life Sci (2005) 62(5):551-577.
10. Caulfield MP: Muscarinic receptors: Characterization, coupling and function. Pharmacol Ther (1993) 58(3):319-379.
11. Felder CC: Muscarinic acetylcholine receptors: Signal transduction through multiple effectors. FASEB J (1995) 9(8):619-625.
12. Zholos AV, Zholos AA, Bolton TB: G-protein-gated TRP-like cationic channel activated by muscarinic receptors: Effect of potential on single-channel gating. J Gen Physiol (2004) 123(5):581-598.
13. Lanzafame AA, Christopoulos A, Mitchelson F: Cellular signaling mechanisms for muscarinic acetylcholine receptors. Receptors Channels (2003) 9(4):241-260.
14. Barathi VA, Weon SR, Beuerman RW: Expression of muscarinic receptors in human and mouse sclera and their role in the regulation of scleral fibroblasts proliferation. Mol Vis (2009) 15:1277-1293.
15. Libert C: Inflammation: A nervous connection. Nature (2003) 421(6921):328-329.
16. Forsgren S, Grimsholm O, Jönsson M, Alfredson H, Danielson P: New insight into the non-neuronal cholinergic system via studies on chronically painful tendons and inflammatory situations. Life Sci (2009) 84(25-26): 865-870.
17. Kawashima K, Fujii T: Expression of non-neuronal acetylcholine in lymphocytes and its contribution to the regulation of immune function. Front Biosci (2004) 9:2063-2085.
18. Kawashima K, Yoshikawa K, Fujii YX, Moriwaki Y, Misawa H: Expression and function of genes encoding cholinergic components in murine immune cells. Life Sci (2007) 80 (24-25):2314-2319.
19. Razani-Boroujerdi S, Behl M, Hahn FF, Pena-Philippides JC, Hutt J, Sopori ML: Role of muscarinic receptors in the regulation of immune and inflammatory responses. J Neuroimmunol (2008) 94(1-2):83-88.
20. Rosas-Ballina M, Tracey KJ: Cholinergic control of inflammation. J Intern Med (2009) 265(6):663-679.
21. Sopori M: Effects of cigarette smoke on the immune system. Nat Rev Immunol (2002) 2(5):372-377.
22. Czura CJ, Friedman SG, Tracey KJ: Neural inhibition of inflammation: The cholinergic anti-inflammatory pathway. J Endotoxin Res (2003) 9(6):409-413
23. Sandberg G: Leukocyte mobilization from the guinea pig spleen by muscarinic cholinergic stimulation. Experientia (1994) 50(1):40-43.
24. Scott A: Acetylcholine in normal and diseased skin. Br J Dermatol (1962) 74:317-322.
25. Wessler I, Reinheimer T, Kilbinger H, Bittinger F, Kirkpatrick CJ, Saloga J, Knop J: Increased acetylcholine levels in skin biopsies of patients with atopic dermatitis. Life Sci (2003) 72 (18-19):2169-2172.
26. Heyer G, Vogelsang M, Hornstein OP: Acetylcholine is an inducer of itching in patients with atopic eczema. J Dermatol (1997) 24(10):621-625. (Pubitemid 27488399)
27. Vogelsang M, Heyer G, Hornstein OP: Acetylcholine induces different cutaneous sensations in atopic and non-atopic subjects. Acta Derm Venereol (1995) 75(6):434-446.
28. Sellheyer K, Krahl D: "Hidradenitis suppurativa" is acne inversa! An appeal to (finally) abandon a misnomer. Int J Dermatol (2005) 44(7):535-540.
29. Kurzen H, Schallreuter KU: Novel aspects in cutaneous biology of acetylcholine synthesis and acetylcholine receptors. Exp Dermatol (2004) 13(Suppl 4):27-30.
30. Hana A, Booken D, Henrich C, Gratchev A, Maas-Szabowski N, Goerdt S, Kurzen H: Functional significance of non-neuronal acetylcholine in skin epithelia. Life Sci (2007) 80(24-25): 2214-2220.
31. Parks RW, Parks TG: Pathogenesis, clinical features and management of hidradenitis suppurativa. Ann R Coll Surg Engl (1997) 79(5):83-89.
32. Busse WW, Lemanske RF Jr: Asthma. N Engl J Med (2001) 344(5): 350-362.
33. Barnes PJ: Chronic obstructive pulmonary disease. N Engl J Med (2000) 343(4):269-280.
34. McQueen DS, Donaldson K, Bond SM, McNeilly JD, Newman S, Barton NJ, Duffin R: Bilateral vagotomy or atropine pre-treatment reduces experimental diesel-soot induced lung inflammation. Toxicol Appl Pharmacol (2007) 219(1):62-71.
35. Gosens R, Zaagsma J, Meurs H, Halayko AJ: Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res (2006) 7:73.
36. Matsui M, Motomura D, Fujikawa T, Jiang J, Takahashi S, Manabe T, Taketo MM: Mice lacking M2 and M3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viable. J Neurosci (2002) 22(24):10627-10632.
37. Michel MC, Parra S: Similarities and differences in the autonomic control of airway and urinary bladder smooth muscle. Naunyn Schmiedebergs Arch Pharmacol (2008) 378(2): 217-224.
38. Gies J-P, Landry Y: Sialic acid is selectively involved in the interaction of agonists with M2 muscarinic acetylcholine receptors. Biochem Biophys Res Commun (1988) 150(2):673-680.
39. Profita M, Giorgi RD, Sala A, Bonanno A, Riccobono L, Mirabella F, Gjomarkaj M, Bonsignore G, Bousquet J, Vignola AM: Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy (2005) 60(11): 1361-1369.
40. Gosens R, Rieks D, Meurs H, Ninaber DK, Rabe KF, Nanninga J, Kolahian S, Halayko AJ, Hiemstra PS, Zuyderduyn S: Muscarinic M3 receptor stimulation increases cigarette smoke-induced IL-8 secretion by human airway smooth muscle cells. Eur Respir J (2009) 34(6):1436-1443.
41. Profita M, Bonanno A, Siena L, Bruno A, Ferraro M, Montalbano AM, Albano GD, Riccobono L, Casarosa P, Pieper MP, Gjomarkaj M: Smoke, choline acetyltransferase, muscarinic receptors, and fibroblast proliferation in chronic obstructive pulmonary disease. J Pharmacol Exp Ther (2009) 329(2):753-763.
42. Bos IS, Gosens R, Zuidhof AB, Schaafsma D, Halayko AJ, Meurs H, Zaagsma J: Inhibition of allergen-induced airway remodeling by tiotropium and budesonide: A comparison. Eur Respir J (2007) 30(4):653-661.
43. Ohta S, Oda N, Yokoe T, Tanaka A, Yamamoto Y, Watanabe Y, Minoguchi K, Ohnishi T, Hirose T, Nagase H, Ohta K et al: Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma. Clin Exp Allergy (2010) 40(8): 1266-1275.
44. Mazzanti G, Tita B, Bolle P, Bonanomi M, Piccinelli D: A comparative study of behavioural and autonomic effects of atropine and Atropa belladonna. Pharmacol Res Commun (1988) Suppl 5: 49-53. (Pubitemid 19058373)
45. Miraldi E, Masti A, Ferri S, Barni Comparini I: Distribution of hyoscyamine and scopolamine in Datura stramonium. Fitoterapia (2001) 72(6):644-648.
46. Tramontana JA, Marderosian AH: Anti-asthmatic drugs as hallucinogens. Pa Med (1967) 70(10):58-60.
47. Zhang W, Fievez L, Cheu E, Bureau F, Rong W, Zhang F, Zhang Y, Advenier C, Gustin P: Anti-inflammatory effects of formoterol and ipratropium bromide against acute cadmium-induced pulmonary inflammation in rats. Eur J Pharmacol (2010) 628(1-3):171-178.
48. Flohr E, Bischoff KO: Oxitropium bromide, a new anticholinergic drug, in a dose-response and placebo comparison in obstructive airway diseases. Respiration (1979) 38(2):98-104.
49. Keam SJ, Keating GM: Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med (2004) 3(4):247-268.
50. Bühling F, Lieder N, Kühlmann UC, Waldburg N, Welte T: Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro. Respir Med (2007) 101(11):2386-2394.
51. Wollin L, Pieper MP: Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD. Pharmacol Ther (2010) 23(4):345-354.
52. Bateman ED, Rennard S, Barnes PJ, Dicpinigaitis PV, Gosens R, Gross NJ, Nadel JA, Pfeifer M, Racké K, Rabe KF, Rubin BK et al: Alternative mechanisms for tiotropium. Pulm Pharmacol Ther (2009) 22(6):533-542.
53. Pahl A, Bauhofer A, Petzold U, Cnota PJ, Maus J, Brune K, Szelenyi S: Synergistic effects of the anti-cholinergic R,R glycopyrrolate with anti-inflammatory drugs. Biochem Pharmacol (2006) 72(12):1690-1696.
54. Chanez P, Burge PS, Dahl R, Creemers J, Chuchalin A, Lamarca R, Garcia Gil E: Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther (2010) 23(1):15-21.
55. Gavald A, Miralpeix M, Ramos I, Otal R, Carreño C, Viñals M, Doménech T, Carcasona C, Reyes B, Vilella D, Gras J et al: Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther (2009) 331(2):740-751.
56. Shi XZ, Sarna SK: Inflammatory modulation of muscarinic receptor activation in canine ileal circular muscle cells. Gastroenterology (1997) 112(3):864-874.
57. Wells RW, Blennerhassett MG: Divergent changes to muscarinic and serotonergic signaling following colitis. Gut (2005) 54(12):1699-1706.
58. Dinan TG, Clarke G, Quigley EM, Scott LV, Shanahan F, Cryan J, Cooney J, Keeling PW: Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: Role of muscarinic receptors. Am J Gastroenterol (2008) 103(10):2570-2576.
59. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med (2003) 348(2):138-150.
60. Fuentes JM, Talamini MA, Fulton WB, Hanly EJ, Aurora AR, De Maio A: General anesthesia delays the inflammatory response and increases survival for mice with endotoxic shock. Clin Vaccine Immunol (2006) 13(2):281-288.
61. Fuentes JM, Fulton WB, Nino D, Talamini MA, Maio AD: Atropine treatment modifies LPS-induced inflammatory response and increases survival. Inflamm Res (2008) 57(3):111-117.
62. Pavlov VA, Ochani M, Gallowitsch-Puerta M, Ochani K, Huston JM, Czura CJ, Al-Abed Y, Tracey KJ: Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. Proc Natl Acad Sci USA (2006) 103(13):5219-5223